12.08.14
Takeda Pharmaceutical Co.’s global oncology business unit, headquartered in Cambridge, MA, is now called Takeda Oncology. Takeda will sustain its approach to oncology R&D while expanding its global commercial network and resources as Takeda Oncology. Takeda is retiring the Millennium brand, replacing it with Takeda Oncology to reflect the new global oncology business unit.
Comprised of Takeda’s global oncology commercial operations, the Oncology Business Unit remains aligned with Takeda’s dedicated global oncology R&D function, the Oncology Therapeutic Area Unit, and Takeda’s Oncology Drug Discovery Unit, and aims to drive the company’s portfolio of products while maintaining a focus on expanding new product launches in the near and longer terms. As a fully integrated unit within Takeda’s global network, the Oncology Business Unit will leverage expertise from diverse oncology markets to help accelerate global and local capabilities.
“Despite the progress made in the fight against cancer, serious unmet needs persist across many forms of the disease,” said Christophe Bianchi, M.D., president, Global Oncology Business Unit. “Takeda Oncology has a deep understanding of patient needs and applies scientific rigor and resources to work to meet these needs. Now, our agile business model optimally organizes us to quickly meet the diverse needs of cancer patients, health care providers and systems around the world, and bring the next generation of cancer treatments to cancer patients who need them.”
The company is currently investigating compounds across more than 17 forms of cancer, including ixazomib in AL amyloidosis and multiple myeloma as well as alisertib in relapsed/refractory peripheral T-cell lymphoma, recurrent ovarian cancer, and small cell lung cancer, among other malignancies.
Comprised of Takeda’s global oncology commercial operations, the Oncology Business Unit remains aligned with Takeda’s dedicated global oncology R&D function, the Oncology Therapeutic Area Unit, and Takeda’s Oncology Drug Discovery Unit, and aims to drive the company’s portfolio of products while maintaining a focus on expanding new product launches in the near and longer terms. As a fully integrated unit within Takeda’s global network, the Oncology Business Unit will leverage expertise from diverse oncology markets to help accelerate global and local capabilities.
“Despite the progress made in the fight against cancer, serious unmet needs persist across many forms of the disease,” said Christophe Bianchi, M.D., president, Global Oncology Business Unit. “Takeda Oncology has a deep understanding of patient needs and applies scientific rigor and resources to work to meet these needs. Now, our agile business model optimally organizes us to quickly meet the diverse needs of cancer patients, health care providers and systems around the world, and bring the next generation of cancer treatments to cancer patients who need them.”
The company is currently investigating compounds across more than 17 forms of cancer, including ixazomib in AL amyloidosis and multiple myeloma as well as alisertib in relapsed/refractory peripheral T-cell lymphoma, recurrent ovarian cancer, and small cell lung cancer, among other malignancies.